7 Biotechnology Stocks to Sell Now

GHDX, ACOR, AMRN, EXEL, TSRX, DSCO, ACHN slump in weekly rankings

   

The overall ratings of seven Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Genomic Health (NASDAQ:GHDX) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. Genomic Health is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. For Portfolio Grader’s specific subcategory of Earnings Revisions, GHDX also gets an F. The stock has a trailing PE Ratio of 167.80. To get an in-depth look at GHDX, get Portfolio Grader’s complete analysis of GHDX stock.

The rating of Acorda Therapeutics (NASDAQ:ACOR) slips from a C to a D. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The stock gets F’s in Earnings Revisions and Sales Growth. The stock price has fallen 12.4% over the past month, worse than the 6.1% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of ACOR stock.

Amarin (NASDAQ:AMRN) earns a D this week, falling from last week’s grade of C. Amarin focuses on developing the treatment for cardiovascular disease in the field of lipid science. The stock receives F’s in Earnings Growth, Earnings Revisions, Equity, and Cash Flow. As of May 15, 2013, 18% of outstanding Amarin shares were held short. For a full analysis of AMRN stock, visit Portfolio Grader.

Exelixis (NASDAQ:EXEL) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Exelixisis a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The stock gets F’s in Earnings Growth, Earnings Momentum, and Equity. Margin Growth and Sales Growth also get F’s. As of May 15, 2013, 20.4% of outstanding Exelixis shares were held short. To get an in-depth look at EXEL, get Portfolio Grader’s complete analysis of EXEL stock.

Trius Therapeutics’ (NASDAQ:TSRX) rating weakens this week, dropping to a D versus last week’s C. Trius Therapeutics is a biopharmaceutical company. The stock receives F’s in Earnings Growth, Earnings Momentum, and Equity. Cash Flow and Sales Growth also get F’s. For more information, get Portfolio Grader’s complete analysis of TSRX stock.

Discovery Laboratories (NASDAQ:DSCO) experiences a ratings drop this week, going from last week’s C to a D. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at DSCO, get Portfolio Grader’s complete analysis of DSCO stock.

The rating of Achillion (NASDAQ:ACHN) slips from a C to a D. Achillion focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The stock also gets an F in Equity. As of May 15, 2013, 12.8% of outstanding Achillion shares were held short. For more information, get Portfolio Grader’s complete analysis of ACHN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, http://investorplace.com/2013/05/7-biotechnology-stocks-to-sell-now-ghdx-acor-amrn-6/.

©2015 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.